WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
FONR
FONAR CORP
$143.34M$102.42M$25.75M$12.16M$1.895.78%4.06%51.20%-8.83%2024-05-13
STRR
STAR EQUITY HOLDINGS INC
$14.06M$45.79M$26.87M$23.22M$1.61-19.88%-15.16%N/A34.19%2024-05-13
IDXX
IDEXX LABORATORIES INC
$44.86B$3.66B$1.22B$845.04M$10.178.72%10.59%25.25%18.57%2024-04-30
RVTY
REVVITY INC
$12.97B$2.75B$1.25B$693.09M$5.56-16.95%-0.20%23.28%20.93%2024-05-09
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$13.91B$4.13B$1.03B$474.62M$9.273.86%12.75%-3.13%14.45%2024-05-09
MEDP
MEDPACE HOLDINGS INC
$12.43B$1.89B$382.14M$282.81M$9.2029.17%21.76%21.53%35.02%2024-04-22
ICLR
ICON PLC
$27.71B$8.12B$1.55B$612.34M$7.464.89%25.62%20.32%4.59%2024-04-25
QGEN
QIAGEN NV
$9.81B$1.97B$688.56M$341.30M$1.50-8.23%5.53%-19.35%11.61%2024-05-01
ENZ
ENZO BIOCHEM INC
$65.06M$12.81M$33.74M$32.57M$0.67N/A-32.08%N/AN/A
SHC
SOTERA HEALTH CO
$3.40B$1.05B$406.83M$51.38M$0.184.54%7.06%N/AN/A2024-05-01
TMO
THERMO FISHER SCIENTIFIC INC
$221.62B$42.86B$11.06B$6.00B$15.52-4.58%11.96%-12.56%16.25%2024-04-24
A
AGILENT TECHNOLOGIES INC
$42.64B$6.74B$1.69B$1.24B$4.22-2.81%6.19%-5.17%3.46%2024-05-21
LH
LABORATORY CORP OF AMERICA HOLDINGS
$18.37B$12.16B$1.55B$418.00M$4.802.51%1.42%-65.84%-11.23%2024-04-23
CSTL
CASTLE BIOSCIENCES INC
$608.02M$219.79M-$45.02M-$57.47M-$2.1460.38%57.35%N/AN/A2024-05-01
DHR
DANAHER CORP
$184.72B$23.89B$8.04B$4.74B$6.44-10.33%6.98%-34.29%11.24%2024-04-23
TWST
TWIST BIOSCIENCE CORP
$1.98B$262.36M-$169.85M-$205.80M-$3.6121.58%51.75%N/AN/A2024-05-03
SERA
SERA PROGNOSTICS INC
$295.07M$306.00k-$34.76M-$36.24M-$1.1614.18%N/AN/AN/A2024-05-08
NEOG
NEOGEN CORP
$3.42B$918.68M$189.32M$11.78M$0.0745.66%17.52%40.00%-35.56%2024-04-09
DGX
QUEST DIAGNOSTICS INC
$14.74B$9.25B$1.69B$854.00M$7.59-6.38%4.20%-6.30%7.09%2024-04-23
MTD
METTLER TOLEDO INTERNATIONAL INC
$28.59B$3.79B$1.17B$788.78M$36.10-3.35%5.23%-6.93%12.17%2024-05-03
WAT
WATERS CORP
$20.38B$2.96B$1.00B$642.23M$10.87-0.52%4.09%-7.88%7.11%2024-05-07
XGN
EXAGEN INC
$27.40M$52.55M-$18.21M-$23.69M-$1.3415.33%10.13%N/AN/A2024-05-13
ACRS
ACLARIS THERAPEUTICS INC
$87.95M$31.25M-$87.99M-$88.48M-$1.275.03%38.41%N/AN/A2024-05-06
IQV
IQVIA HOLDINGS INC
$45.90B$14.98B$3.26B$1.36B$7.393.98%7.55%26.98%42.22%2024-04-25
NTRA
NATERA INC
$11.04B$1.08B-$383.28M-$434.80M-$3.7831.99%33.26%N/AN/A2024-05-07
EXAS
EXACT SCIENCES CORP
$12.54B$2.50B$52.20M-$204.15M-$1.1319.93%40.63%N/AN/A2024-05-07
PSNL
PERSONALIS INC
$75.25M$73.48M-$94.95M-$108.30M-$2.2512.97%14.23%N/AN/A2024-05-01
DRIO
DARIOHEALTH CORP
$45.05M$20.35M-$54.38M-$63.51M-$1.93-26.41%22.45%N/AN/A2024-05-09
OLK
OLINK HOLDING AB (PUBL)
$2.92B$169.60M-$20.05M-$31.60M-$0.2521.27%N/AN/AN/A2024-05-09
FLGT
FULGENT GENETICS INC
$646.33M$289.21M-$134.12M-$167.83M-$5.63-53.27%68.41%N/AN/A2024-05-03
NEO
NEOGENOMICS INC
$2.01B$591.64M-$8.37M-$87.97M-$0.7016.07%16.41%N/AN/A2024-05-06
GH
GUARDANT HEALTH INC
$2.51B$563.95M-$433.31M-$479.45M-$4.2825.45%44.14%N/AN/A2024-05-07
STIM
NEURONETICS INC
$141.64M$71.35M-$22.76M-$30.19M-$1.059.42%6.22%N/AN/A2024-05-07
DMTK
DERMTECH INC
$24.31M$15.30M-$95.04M-$100.89M-$3.095.36%44.33%N/AN/A2024-05-02
BGLC
BIONEXUS GENE LAB CORP
$12.47M$10.34M-$2.87M-$3.09M-$0.22-8.80%N/AN/AN/A
BNR
BURNING ROCK BIOTECH LTD
$74.54M$74.64MN/A-$90.79M-$0.89-6.20%20.19%N/AN/A2024-05-28
RDNT
RADNET INC
$3.33B$1.62B$265.49M$3.04M$0.0513.05%10.64%-73.68%-40.49%2024-05-07
BIAF
BIOAFFINITY TECHNOLOGIES INC
$19.19M$321.49k-$7.04M-$7.24M-$0.4212,989.94%N/AN/AN/A2024-03-29
APDN
APPLIED DNA SCIENCES INC
$6.96M$9.00M-$5.89M-$7.29M-$0.55-53.31%16.79%N/AN/A2024-05-09
PRPO
PRECIPIO INC
$9.51M$13.26M-$7.53M-$9.07M-$7.4440.22%33.52%N/AN/A2024-05-15
MDXH
MDXHEALTH SA
$7.00M$70.19M-$20.47M-$43.10M-$16.6089.43%N/AN/AN/A2024-05-08
BDSX
BIODESIX INC
$138.63M$49.09M-$37.10M-$52.15M-$0.6428.46%19.16%N/AN/A2024-05-09
CDNA
CAREDX INC
$548.33M$280.32M-$182.19M-$190.28M-$3.54-12.89%29.63%N/AN/A2024-05-08
GTH
GENETRON HOLDINGS LTD
$123.44M$94.31M-$101.00M-$117.16M-$3.7812.32%43.63%N/AN/A
LAB
STANDARD BIOTOOLS INC
$786.22M$106.34M-$65.66M-$74.66M-$0.948.57%-1.20%N/AN/A2024-05-07
NDRA
ENDRA LIFE SCIENCES INC
$6.40M$0.00-$9.78M-$10.06M-$1.58N/A-100.00%N/AN/A2024-05-13
CHEK
CHECK-CAP LTD
$18.19M$0.00-$19.08M-$17.62M-$3.02N/AN/AN/AN/A2024-03-29
PRPH
PROPHASE LABS INC
$116.75M$62.71M-$9.64M-$10.48M-$0.63-57.04%36.60%N/AN/A2024-05-09
XWEL
XWELL INC
$7.06M$30.26M-$30.04M-$34.61M-$8.18-61.07%-9.74%N/AN/A2024-05-13
OPK
OPKO HEALTH INC
$836.39M$863.50M-$65.62M-$188.86M-$0.25-14.01%-2.70%N/AN/A2024-05-01
NOTV
INOTIV INC
$282.15M$585.17M$59.57M-$33.21M-$1.30-0.18%81.64%N/AN/A2024-05-09
ME
23ANDME HOLDING CO
$256.91M$247.99M-$490.64M-$521.97M-$1.11-19.40%N/AN/AN/A2024-05-26
VNRX
VOLITIONRX LTD
$62.13M$775.30k-$33.68M-$35.32M-$0.50153.04%N/AN/AN/A2024-05-08
ISPC
ISPECIMEN INC
$2.11M$9.93M-$9.02M-$11.10M-$1.23-4.56%N/AN/AN/A2024-05-02
GENE
GENETIC TECHNOLOGIES LTD
$667.11k$5.55MN/A-$8.33M-$2.98-3.27%136.93%N/AN/A
MYGN
MYRIAD GENETICS INC
$1.92B$753.20M-$186.10M-$263.30M-$3.1811.03%-1.10%N/AN/A2024-05-01
PRE
PRENETICS GLOBAL LTD
$47.56M$68.79MN/A-$44.17M-$4.05-11.02%N/AN/AN/A
PMD
PSYCHEMEDICS CORP
$16.83M$22.10M-$768.00k-$4.15M-$0.72-12.45%-12.33%N/AN/A2024-05-07
ILMN
ILLUMINA INC
$21.82B$4.50B-$608.00M-$1.16B-$7.34-1.75%6.21%N/AN/A2024-04-23
OCX
ONCOCYTE CORP
$24.20M-$2.36M-$54.87M-$58.14M-$9.48N/AN/AN/AN/A2024-05-09
AWH
ASPIRA WOMEN's HEALTH INC
$32.04M$9.18M-$20.74M-$20.91M-$2.4916.43%25.66%N/AN/A2024-05-09
MMA
ALTA GLOBAL GROUP LTD
N/A$1.54M-$16.12M-$20.60M-$5.2663.35%N/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$15.55M$61.44MN/A-$28.60MN/A-7.36%-8.74%N/AN/A2024-05-07
CNTG
CENTOGENE NV
$19.59M$55.12M-$44.39M-$61.44M-$1.58N/AN/AN/AN/A2024-05-29
TTOO
T2 BIOSYSTEMS INC
$12.15M$11.00M-$41.78M-$49.84M-$157.45-53.80%1.18%N/AN/A2024-05-21
MYNZ
MAINZ BIOMED NV
$16.10MN/AN/AN/AN/AN/AN/AN/AN/A2024-05-13

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Mar 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 38.7% over the past year, overperforming other diagnostic & research stocks by 34 percentage points.

2. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the second best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 10.61% over the past year, overperforming other diagnostic & research stocks by 6 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 8.16% from Idexx Laboratories's current stock price of $539.93.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 3.74% over the past year, underperforming other diagnostic & research stocks by -1 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.98%, which is 1 percentage points higher than the diagnostic & research industry average of 1.61%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.13%, which is 1 percentage points higher than the diagnostic & research industry average of 1.61%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.32%, which is the same as the diagnostic & research industry average of 1.61%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.28% in the last day, and down -0.17% over the last week. Opko Health was the among the top gainers in the diagnostics & research industry, gaining 12.15% yesterday.

OPKO Health shares are trading higher after Labcorp announced it will acquire select assets of OPKO's BioReference Health for a purchase price of $237.5 million.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 3.74% in the past year. It has underperformed other stocks in the diagnostic & research industry by -1 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -47.74% in the past year. It has underperformed other stocks in the diagnostic & research industry by -52 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 38.7% in the past year. It has overperformed other stocks in the diagnostic & research industry by 34 percentage points.

Are diagnostic & research stocks a good buy now?

45.24% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 0.55% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 37.37x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.